{"id":"rosiglitazone-and-metformin-combination-tablet","safety":{"commonSideEffects":[{"rate":"10–15","effect":"Weight gain"},{"rate":"5–10","effect":"Edema"},{"rate":"5–10","effect":"Hypoglycemia"},{"rate":"10–20","effect":"Gastrointestinal disturbance (metformin-related)"},{"rate":"5–10","effect":"Headache"},{"rate":"5–10","effect":"Upper respiratory tract infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"This combination tablet pairs a thiazolidinedione (rosiglitazone) that enhances insulin sensitivity in muscle and adipose tissue with a biguanide (metformin) that decreases hepatic gluconeogenesis and improves glucose utilization. Together, they address multiple pathophysiologic defects in type 2 diabetes through complementary mechanisms, reducing both fasting and postprandial hyperglycemia.","oneSentence":"Rosiglitazone improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), while metformin reduces hepatic glucose production and improves peripheral glucose uptake.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:45.242Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT00885352","phase":"PHASE3","title":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-15","conditions":"Type 2 Diabetes Mellitus","enrollment":313},{"nctId":"NCT00350779","phase":"PHASE3","title":"Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06-12","conditions":"Type 2 Diabetes Mellitus","enrollment":262},{"nctId":"NCT00399711","phase":"PHASE3","title":"Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":560},{"nctId":"NCT00933309","phase":"PHASE1","title":"The Impact of Obesity and Obesity Treatments on Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-07","conditions":"Breast Cancer","enrollment":25},{"nctId":"NCT00295633","phase":"PHASE3","title":"A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-03","conditions":"Diabetes Mellitus, Type 2","enrollment":565},{"nctId":"NCT00680745","phase":"PHASE3","title":"Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Type 2 Diabetes","enrollment":597},{"nctId":"NCT00776607","phase":"NA","title":"Randomized Controlled Trial of Insulin Versus Tablets for Latent Autoimmune Diabetes in Adults (LADA)","status":"UNKNOWN","sponsor":"Abertawe Bro Morgannwg University NHS Trust","startDate":"2007-04","conditions":"Latent Autoimmune Diabetes in Adults LADA","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"rosiglitazone and metformin combination tablet","genericName":"rosiglitazone and metformin combination tablet","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rosiglitazone improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), while metformin reduces hepatic glucose production and improves peripheral glucose uptake. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}